Vector Gateway™ pDONR™221
Product Image
Invitrogen™

Vector Gateway™ pDONR™221

La tecnología Gateway™ permite una clonación rápida de uno o más genes en prácticamente cualquier sistema de expresión de lasMás información
Have Questions?
Número de catálogoCantidad
125360176 μg
Número de catálogo 12536017
Precio (USD)
-
Cantidad:
6 μg
Ask our AI about this Product
La tecnología Gateway™ permite una clonación rápida de uno o más genes en prácticamente cualquier sistema de expresión de las proteínas. Cuando tenga un clon de entrada, podrá recombinar el gen de interés en una serie de vectores de expresión adaptados para el uso en la tecnología Gateway™. El producto de la reacción en cadena de la polimerasa (PCR) se clona de forma direccional con eficacias típicas de >99 %. El vector pDONR™221 tiene un origen de plásmido pUC para alta producción de plásmidos y sitios de secuenciación M13 universales para la facilidad de uso.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Tipo de productoVector de expresión de destino del sistema Gateway
Cantidad6 μg
VectorpDONR
Método de clonaciónGateway
Línea de productosGateway™, pDONR™
Unit SizeEach
Contenido y almacenamiento
Vector pDONR221™ 6μg, liofilizado en tampón TE, pH 8.0. Tras su recepción, conservar a -20°C.
Ready-to-use Bacterial Growth Media

Ready-to-use Bacterial Growth Media

See how these mediums can help with critical aspects of cloning!

Gibco LB Broth

Invitrogen S.O.C. Medium

Invitrogen One Shot LB Agar*

*Only available in North America and selected European countries

Have questions about this product? Ask our AI assisted search.
This is an AI-powered search and may not always get things right. You can help us make it better with a thumbs up or down on individual answers or by selecting the “Give feedback" button. Your search history and customer login information may be retained by Thermo Fisher and processed in accordance with our Privacy Notice.

Preguntas frecuentes

I performed a BP reaction and got high background after transformation. Can you please offer some troubleshooting tips?

– Check whether the reaction was transformed into an E.coli strain containing the F' episome and the ccdA gene – use an E.coli strain that does not contain the F' episome, e.g. DH10B, TOP10.
– Deletion (full or partial) of the ccdB gene – propagate in media with 50-100 mg/mL ampicillin and 15-30 µg/mL chloramphenicol.
– Contamination from another resistant strain.
– Check whether proper amount of DNA was used in the reaction.

I performed a BP reaction and got two distinct types of colonies (large and small) after transformation. How should I proceed?

Typically when both large and small colonies are produced following BP recombination, we recommend screening several of both of the small and large colony types by analytical restriction digest, PCR with gene specific primers, or by sequencing to determine what you have and decide on the best course forward. If one of the colonies you analyze contains your desired entry clone, then you may proceed with this entry clone to an LR reaction to produce your desired expression clone.

There are several possible causes of this issue:

– Plasmid was lost during culture due to large size or toxicity – To improve results next time you perform a BP reaction with a tricky insert, you may try incubating your transformation plate at 30 degrees C and/or use Stbl2 E.coli to stabilize the plasmid. We also recommend performing the BP reaction positive control pEXP7-Tet alongside your BP cloning reaction of interest; the results of that control reaction will let you know whether the large and small colony phenotype is specific to your insert of interest.

– Deletions (full or partial) or point mutations in the ccdB gene – A negative BP reaction control (with no BP clonase added) should not produce any colonies – If a no BP clonase negative control produces colonies, then the ccdB/chlorophenicol cassette is compromised and we recommend to obtain a new pDONR vector.br/>
– Background on antibiotic selection plate due to contamination or expired antibiotic – If you run a no plasmid added transformation negative control plate, then this plate should not produce any colonies. Colonies on transformation negative control plate suggests contamination or need to make fresh plates.

I performed a BP reaction and got no colonies after transformation, and the recombination positive control was not successful. Can you please offer some suggestions?

– Check the competent cells with pUC19 transformation.
– Increase the amount plated.

I performed a BP reaction and got few or no colonies after transformation, whereas the transformation control gave colonies. Can you please offer some suggestions?

– Increase the incubation time up to 18 hours.
– Make sure to treat reactions with proteinase K before transformation.
– Check whether the correct antibiotic was used for selection.
– Check whether the att site sequences are correct.
– Check whether the correct Clonase enzyme was used and whether it was functional.
– Check whether the recommended amount of DNA was used in the reaction.
– Check primer design and try gel/PEG purifying the attB-PCR product.
– If the attB-PCR product or linear attB Expression clone is too long (>5 kb), incubate the BP reaction overnight.

I forgot to add proteinase K to my BP reaction. Can I continue?

You may continue, but the recombination efficiency will drop by approximately 10 fold.

Figuras

Documentos y descargas

Certificados

Se muestran 0 resultados, busque arriba un certificado específico

Hojas de datos de seguridad

Información vectorial

Nombre del vector
Mapas de vectores
Poliligador
Secuencia
Restricción
pcDNA6/BioEase-GW/lacZ

Citations & References (4)

Citations & References
Abstract
Dual-tagging system for the affinity purification of mammalian protein complexes.
Authors:Giannone RJ, McDonald WH, Hurst GB, Huang Y, Wu J, Liu Y, Wang Y,
Journal:Biotechniques
PubMed ID:17907572
'Although affinity purification coupled with mass spectrometry (MS) provides a powerful tool to study protein-protein interactions, this strategy has encountered numerous difficulties when adapted to mammalian cells. Here we describe a Gateway-compatible dual-tag affinity purification system that integrates regulatable expression, tetracysteine motifs, and various combinations ofaffinity tags to facilitate the ... More
Development of R4 gateway binary vectors (R4pGWB) enabling high-throughput promoter swapping for plant research.
Authors:Nakagawa T, Nakamura S, Tanaka K, Kawamukai M, Suzuki T, Nakamura K, Kimura T, Ishiguro S,
Journal:Biosci Biotechnol Biochem
PubMed ID:18256458
We developed a new series of Gateway binary vectors, R4pGWBs, that are plant transformation vectors designed for one-step construction of chimeric genes between any promoter and any cDNA. The structure of R4pGWBs is almost the same as the promoterless type of improved pGWBs (ImpGWBs), except that the attR1 site is ... More
Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Authors:Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, Tan TH, Colburn NH,
Journal:Mol Cell Biol
PubMed ID:16449643
Programmed cell death 4 (Pdcd4) suppresses neoplastic transformation by inhibiting the activation of c-Jun and consequently AP-1-dependent transcription. We report that Pdcd4 blocks c-Jun activation by inhibiting the expression of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)/hematopoietic progenitor kinase 1, a kinase upstream of Jun N-terminal kinase (JNK). cDNA ... More
Human protein factory for converting the transcriptome into an in vitro-expressed proteome,.
Authors:Goshima N, Kawamura Y, Fukumoto A, Miura A, Honma R, Satoh R, Wakamatsu A, Yamamoto J, Kimura K, Nishikawa T, Andoh T, Iida Y, Ishikawa K, Ito E, Kagawa N, Kaminaga C, Kanehori K, Kawakami B, Kenmochi K, Kimura R, Kobayashi M, Kuroita T, Kuwayama H, Maruyama Y, Matsuo K, Minami K, Mitsubori M, Mori M, Morishita R, Murase A, Nishikawa A, Nishikawa S, Okamoto T, Sakagami N, Sakamoto Y, Sasaki Y, Seki T, Sono S, Sugiyama A, Sumiya T, Takayama T, Takayama Y, Takeda H, Togashi T, Yahata K, Yamada H,
Journal:Nat Methods
PubMed ID:19054851
Appropriate resources and expression technology necessary for human proteomics on a whole-proteome scale are being developed. We prepared a foundation for simple and efficient production of human proteins using the versatile Gateway vector system. We generated 33,275 human Gateway entry clones for protein synthesis, developed mRNA expression protocols for them ... More
4 total citations

Compartir número de catálogo, nombre o enlace.

1x1 image pixel for data collection